Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
XRTX | US
-0.01
-3.66%
Healthcare
Biotechnology
30/06/2024
20/03/2026
0.40
0.41
0.43
0.37
XORTX Therapeutics Inc. a late stage clinical pharmaceutical company engages in the development and commercialization of therapies to treat progressive kidney diseases diabetes insulin resistance metabolic syndrome diabetes diabetic nephropathy and infection. It develops XRx-008 a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101 an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and acute kidney injury (AKI) associated health consequences; and XRX-225 a program for treatment of type 2 diabetic nephropathy. The company has a collaboration and license agreements with the Icahn School of Medicine to study the incidence of AKI and hyperuricemia in patients hospitalized with COVID-19; and with the University of Florida Research Foundation Inc. XORTX Therapeutics Inc. is based in Alberta Beach Canada.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
83.6%1 month
76.5%3 months
72.5%6 months
92.4%-
0.96
2.02
0.03
0.02
0.09
-
-
-3.30M
1.19M
1.19M
-
-
-
-
-29.36
0.07
1.11
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.12
Range1M
0.12
Range3M
0.26
Rel. volume
1.06
Price X volume
19.67K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Kala Pharmaceuticals Inc | KALA | Biotechnology | 0.2368 | 1.30M | -3.70% | n/a | 268.29% |
| Vaxxinity Inc. Class A Common Stock | VAXX | Biotechnology | 0.01 | 1.27M | 9900.00% | n/a | 113.12% |
| Orgenesis Inc | ORGS | Biotechnology | 0.25 | 1.19M | -16.67% | n/a | -84.02% |
| RedHill Biopharma Ltd | RDHL | Biotechnology | 0.879 | 1.13M | -0.99% | n/a | 65.80% |
| International Stem Cell Corporation | ISCO | Biotechnology | 0.136 | 1.09M | -4.83% | n/a | 0.00% |
| Phio Pharmaceuticals Corp | PHIO | Biotechnology | 1.22 | 1.05M | 3.39% | n/a | 0.00% |
| Galmed Pharmaceuticals Ltd | GLMD | Biotechnology | 0.6 | 904.19K | 2.83% | n/a | 0.00% |
| Evofem Biosciences Inc | EVFM | Biotechnology | 0.0085 | 852.80K | 0.00 | 0.00% | |
| Pasithea Therapeutics Corp. Common Stock | KTTA | Biotechnology | 0.797 | 832.79K | 1.91% | n/a | 0.00% |
| Virax Biolabs Group Limited Ordinary Shares | VRAX | Biotechnology | 0.1732 | 752.03K | -4.63% | n/a | 4.18% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.09 | 1.15M | -2.34% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.09 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.02 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 72.47 | - | Par |
| Debt to Equity | 0.03 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 1.19M | - | Emerging |